Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
11 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development...